• money9
  • Insurance
  • Saving
  • Mutual Funds
  • Mirae Asset MF
  • Breaking Briefs
downloadDownload The App
Close
  • Home
  • Videos
  • Podcast
  • Banking
  • Bulletin
  • Gold
  • Healthcare
  • Real Estate
  • Tax
  • Travel
  • Survey 2023
  • Survey Report
  • Breaking Briefs
  • Insurance
  • Savings
  • Loan
  • Crypto
  • Investment
  • Mutual Funds
  • Real Estate
  • Tax
  • Exclusive
  • Home » Biocon Ltd.

Biocon Ltd.

  • Markets

    Money9 Covid25 Index continues to outperform Nifty50, Nifty Pharma

    Money9 Covid25 Index advanced 2.78% while Nifty50 and Nifty Pharma logged gains of 0.82% and 2.57%, respectively

  • Equities

    Money9 Covid25 Index & Nifty 50 hovering near their record highs

    The base period for the Money9 Covid25 Index is March 24, 2020, when India went into lockdown, and the base value of the index has been kept at 100

  • Equities

    Nifty50 not the only index at all-time high

    This week, both Nifty and Money9 Covid25 touched their record highs of 15,469 and 312.67, respectively

  • Equities

    Here’s how the Money9 Covid25 index performed this week

    This week, Money9 Covid25 Index outperformed the Nifty Pharma index by 1.9 percentage points but underperformed the Nifty 50 by 68 basis points

  • Equities

    Money9 Covid25 Index: Check out its performance

    In the current week, benchmark index Nifty 50 ended with losses of 1% whereas Money9 Covid25 Index fell 0.7%

  • Equities

    Launching Money9 Covid25 Index: These 25 Covid-stocks are beating Dalal Street

    The index consists of 25 Covid-stocks broadly categorised into five verticals of the healthcare industry — vaccine manufacturers, pharma companies,

Latest

  • 1. Know the correct way to get KYC done!
  • 2. Why health insurance claim gets rejected?
  • 3. Power to Respond!
  • 4. What is Asset Under Management?
  • 5. No Worries on Medical Expenses!
  • Contact Us
  • About Us
  • Privacy & Cookies Notice
  • Complaint Redressal
  • Copyright © 2026 Money9. All rights reserved.
  • share
  • Facebook
  • Twitter
  • Whatsapp
  • LinkedIn
  • Telegram
close